Kenvue Stock Falls 13% in Its Worst Day on Record -- WSJ

Dow Jones
2025/10/17

By WSJ Staff

Shares of Kenvue fell 13% Thursday to $14.11, its lowest finish since the consumer healthcare firm spun off from Johnson & Johnson in 2023. The decline was the sharpest on record for Kenvue, according to Dow Jones Market Data. The fall surpassed the day last month that President Trump warned that the active ingredient in Kenvue's Tylenol is a potential cause of autism. Kenvue has said that Tylenol is safe and that the science shows no clear link between it and autism.

This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).

(END) Dow Jones Newswires

October 16, 2025 16:43 ET (20:43 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10